• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Increasing evidence that the risks of rhAPC may outweigh its benefits.

作者信息

Eichacker Peter Q, Natanson Charles

出版信息

Intensive Care Med. 2007 Mar;33(3):396-9. doi: 10.1007/s00134-007-0556-8. Epub 2007 Feb 15.

DOI:10.1007/s00134-007-0556-8
PMID:17325833
Abstract
摘要

相似文献

1
Increasing evidence that the risks of rhAPC may outweigh its benefits.越来越多的证据表明，重组人活化蛋白C（rhAPC）的风险可能超过其益处。
Intensive Care Med. 2007 Mar;33(3):396-9. doi: 10.1007/s00134-007-0556-8. Epub 2007 Feb 15.
2
Risks and benefits of activated protein C treatment for severe sepsis.活化蛋白C治疗严重脓毒症的风险与益处
N Engl J Med. 2002 Sep 26;347(13):1027-30. doi: 10.1056/NEJMsb020574.
3
Adverse events and clinical outcome associated with drotrecogin alfa-activated: a single-center experience of 498 patients over 8 years.与活化型重组人凝血因子 VIIa 相关的不良事件和临床结局：8 年中 498 例患者的单中心经验。
J Crit Care. 2012 Jun;27(3):320.e7-12. doi: 10.1016/j.jcrc.2011.07.004. Epub 2011 Dec 14.
4
Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.活化型重组人组织型纤溶酶原激活物治疗严重脓毒症的有效性和安全性：一项荟萃分析和元回归研究。
Lancet Infect Dis. 2012 Sep;12(9):678-86. doi: 10.1016/S1473-3099(12)70157-3. Epub 2012 Jul 17.
5
Recombinant human activated protein C, package labeling, and hemorrhage risks.重组人活化蛋白C、包装标签与出血风险。
Crit Care Med. 2009 Jan;37(1):327-9. doi: 10.1097/CCM.0b013e3181935102.
6
Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.重新评估重组人活化蛋白C治疗脓毒症：开展新的随机对照试验的时候了。
Crit Care Med. 2005 Oct;33(10):2426-8. doi: 10.1097/01.ccm.0000183002.26587.ff.
7
[Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].我们还能承担得起重症监护医学的发展吗？回复：《德国医学周刊》2004年第1 - 2期的文章
Dtsch Med Wochenschr. 2004 Jul 30;129(31-32):1698; author reply 1699-70. doi: 10.1055/s-2004-829019.
8
Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.评估重组人活化蛋白C在成人严重脓毒症中的应用：一项加拿大多中心观察性研究。
Intensive Care Med. 2007 Mar;33(3):517-23. doi: 10.1007/s00134-007-0555-9. Epub 2007 Feb 15.
9
Is there increasing evidence that the risks of rhAPC may outweigh its benefits?是否有越来越多的证据表明重组人活化蛋白C（rhAPC）的风险可能超过其益处？
Intensive Care Med. 2007 Aug;33(8):1485-6; author reply 1489. doi: 10.1007/s00134-007-0707-y. Epub 2007 Jun 12.
10
What is the role of recombinant activated protein C in the management of sepsis?重组活化蛋白C在脓毒症治疗中的作用是什么？
Medwave. 2016 Dec 20;16(Suppl5):e6801. doi: 10.5867/medwave.2016.6801.

引用本文的文献

1
How the context of reception affects the meaning of RCT evidence.接受语境如何影响 RCT 证据的意义。
Health (London). 2024 Mar;28(2):253-271. doi: 10.1177/13634593221134011. Epub 2022 Nov 5.
2
An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.脓毒症和感染性休克的另一种病理生理模式：优化抗菌治疗的意义。
Virulence. 2014 Jan 1;5(1):80-97. doi: 10.4161/viru.26913. Epub 2013 Nov 1.
3
The late phase of sepsis is characterized by an increased microbiological burden and death rate.

本文引用的文献

1
Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.评估重组人活化蛋白C在成人严重脓毒症中的应用：一项加拿大多中心观察性研究。
Intensive Care Med. 2007 Mar;33(3):517-23. doi: 10.1007/s00134-007-0555-9. Epub 2007 Feb 15.
2
Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.意大利重症监护病房中活化蛋白C（重组人活化蛋白C）的使用情况：一项全国性调查的结果
Intensive Care Med. 2007 Mar;33(3):426-34. doi: 10.1007/s00134-007-0554-x. Epub 2007 Feb 15.
3
The value of phase 4 clinical testing.
脓毒症的晚期阶段以微生物负担增加和死亡率升高为特征。
Crit Care. 2011 Jul 28;15(4):R183. doi: 10.1186/cc10332.
4
Is There NO Treatment For Severe Sepsis?严重脓毒症是否无药可医？
Libyan J Med. 2008 Mar 1;3(1):34-8. doi: 10.4176/071018.
5
Early antimicrobial therapy in severe sepsis and septic shock.严重脓毒症和脓毒性休克的早期抗菌治疗。
Curr Infect Dis Rep. 2010 Sep;12(5):336-44. doi: 10.1007/s11908-010-0128-x.
6
APCAP--activated protein C in acute pancreatitis: a double-blind randomized human pilot trial.急性胰腺炎中活化蛋白 C（APCAP）：一项双盲随机人体初步试验。
Crit Care. 2010;14(4):R139. doi: 10.1186/cc9203. Epub 2010 Jul 27.
7
The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes.重症脓毒症患者的国际PROGRESS注册研究：活化蛋白C的使用与患者预后
Crit Care. 2009;13(3):R103. doi: 10.1186/cc7936. Epub 2009 Jun 30.
8
Can we predict the effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and ethyl pyruvate.我们能否预测 NF-κB 抑制在脓毒症中的作用？以小白菊内酯和丙酮酸乙酯为例的研究。
Expert Opin Investig Drugs. 2009 Aug;18(8):1047-60. doi: 10.1517/13543780903018880.
9
Saponin fraction from Astragalus membranaceus roots protects mice against polymicrobial sepsis induced by cecal ligation and puncture by inhibiting inflammation and upregulating protein C pathway.黄芪根皂甙通过抑制炎症和上调蛋白 C 途径保护小鼠免受盲肠结扎和穿刺诱导的多微生物脓毒症。
J Nat Med. 2009 Oct;63(4):421-9. doi: 10.1007/s11418-009-0348-2. Epub 2009 Jun 24.
10
Scientific and clinical challenges in sepsis.脓毒症的科学与临床挑战。
Curr Pharm Des. 2009;15(16):1918-35. doi: 10.2174/138161209788453248.
4期临床试验的价值。
N Engl J Med. 2006 Jan 26;354(4):413-5. doi: 10.1056/NEJMe058272.
4
First, gather the data.首先，收集数据。
N Engl J Med. 2006 Jan 26;354(4):329-31. doi: 10.1056/NEJMp058235.
5
Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.重新评估重组人活化蛋白C治疗脓毒症：开展新的随机对照试验的时候了。
Crit Care Med. 2005 Oct;33(10):2426-8. doi: 10.1097/01.ccm.0000183002.26587.ff.
6
Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.来自全球开放性试验ENHANCE的重组人活化蛋白C治疗严重脓毒症：生存和安全性的进一步证据及早期治疗的意义
Crit Care Med. 2005 Oct;33(10):2266-77. doi: 10.1097/01.ccm.0000181729.46010.83.
7
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.重组人活化蛋白C用于严重脓毒症且死亡风险较低的成人患者。
N Engl J Med. 2005 Sep 29;353(13):1332-41. doi: 10.1056/NEJMoa050935.
8
Substantiating the concerns about recombinant human activated protein C use in sepsis.证实对重组人活化蛋白C用于脓毒症治疗的担忧。
Crit Care Med. 2004 Dec;32(12):2542-3. doi: 10.1097/01.ccm.0000148090.94378.6a.
9
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.重组人活化蛋白C用于脓毒症治疗：试验结果不一致、作用机制不明以及安全性问题导致了标签限制和开展IV期试验的必要性。
Crit Care Med. 2003 Jan;31(1 Suppl):S94-6. doi: 10.1097/00003246-200301001-00013.
10
Efficacy and safety of recombinant human activated protein C for severe sepsis.重组人活化蛋白C治疗严重脓毒症的疗效与安全性
N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001.